{"id":"bay-77-1931","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a small-molecule direct thrombin inhibitor, BAY 77-1931 binds directly to the catalytic site of thrombin, preventing the conversion of fibrinogen to fibrin and thereby inhibiting coagulation cascade amplification. This mechanism allows for more predictable anticoagulation compared to indirect inhibitors like heparin, which require antithrombin as a cofactor.","oneSentence":"BAY 77-1931 is a direct thrombin inhibitor that blocks the active site of thrombin to prevent blood clot formation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:22:20.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prevention and treatment"}]},"trialDetails":[{"nctId":"NCT03074058","phase":"PHASE1","title":"Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-10","conditions":"Clinical Pharmacology","enrollment":20},{"nctId":"NCT01518387","phase":"PHASE3","title":"Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-01","conditions":"Hyperphosphatemia","enrollment":43},{"nctId":"NCT00769496","phase":"PHASE2","title":"BAY 77-1931 Long-term Extension From Phase II Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-01","conditions":"Hyperphosphatemia","enrollment":145},{"nctId":"NCT01514851","phase":"PHASE3","title":"Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-01","conditions":"Hyperphosphatemia","enrollment":259}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BAY 77-1931","genericName":"BAY 77-1931","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY 77-1931, also known as lanthanum carbonate, is a small molecule used in clinical trials to treat hyperphosphatemia. It has been studied in a phase III double-blind comparative study with calcium carbonate to determine its efficacy in patients with hyperphosphatemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}